SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
UC Davis now combines manufacturing and clinical-site roles for CER-1236, while SRX’s proposed acquisition of CERo Therapeutics remains pending.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SRX Global (SRXH) announced activation of UC Davis as a clinical site for CERo Therapeutics’ ongoing Phase 1 CERTAIN-T trial. The study evaluates CER-1236 in blood cancers. UC Davis is also its primary manufacturing site; SRX expects the activation to expand recruitment capacity and streamline treatment logistics.
Previously reported findings covered six patients in two cohorts. All three second-cohort patients completed the 28-day assessment without dose-limiting toxicity. Investigators reported clinical improvement in two patients, with formal response assessments ongoing. One patient with refractory acute myeloid leukemia underwent donor stem cell transplantation 71 days after infusion. Enrollment has expanded to myelodysplastic syndromes and myelofibrosis.
SRX’s definitive agreement to acquire CERo Therapeutics remains subject to customary closing conditions. The clinical findings are preliminary and do not establish safety or efficacy.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Definitive purchase agreement would make CERo Therapeutics a wholly owned SRX subsidiary.
- Minor pointUC Davis activation advances clinical operations at SRX’s proposed acquisition target, CERo Therapeutics.
- Minor point. Forward-looking: it has not happened yet and may not happen.Recruitment capacity and treatment logistics are expected by SRX to improve through UC Davis’ manufacturing capabilities.
- Minor pointThree second-cohort patients completed the 28-day dose-limiting toxicity assessment without a dose-limiting toxicity.
- Minor pointJune 2026 safety update reported no cytokine release syndrome, immune-related neurotoxicity, or treatment-related severe adverse events during the assessment window.
3 minor points
- Minor pointClinical improvement in two patients was reported by investigators in CERo’s trial.
- Minor pointOne refractory acute myeloid leukemia patient underwent donor stem cell transplantation 71 days after CER-1236 infusion.
- Minor pointTrial enrollment expansion adds myelodysplastic syndromes and myelofibrosis to CERo’s study.
Negative
- Minor pointProposed CERo acquisition remains pending, subject to customary closing conditions.
- Minor pointFormal response assessments remained ongoing for the reported clinical improvements.
Key Figures
- Patients without DLT
- 3 patients
- Second cohort; all completed the DLT assessment without a DLT
- DLT assessment period
- 28 days
- Second cohort assessment completed without a DLT
- Patients with clinical improvement
- 2 patients
- Formal response assessments remained ongoing
Historical Context
-
Definitive CERo purchase agreement and initial CERTAIN-T cohort findings were disclosed.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
dose-limiting toxicity medical
cytokine release syndrome medical
allogeneic stem cell transplantation medical
pharmacokinetics medical
pharmacodynamics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline treatment logistics
Update follows SRX’s previously announced definitive agreement to acquire CERo Therapeutics
NORTH PALM BEACH, Fla., Oct. 26, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that the University of California, Davis (“UC Davis”) has been activated as a clinical trial site for CERTAIN-T, the ongoing Phase 1 study evaluating CER-1236 in patients with hematologic malignancies being conducted by CERo Therapeutics, the operating subsidiary of CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo Holdings” and, together with CERo Therapeutics, “CERo”), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms. UC Davis also serves as the primary manufacturing site for CER-1236.
The activation of UC Davis is expected to expand patient recruitment capacity while leveraging the site's existing manufacturing capabilities to streamline treatment logistics.
“Activating UC Davis as a clinical site is a meaningful operational milestone for CERo and for the CERTAIN-T study,” said Kent Cunningham, Chief Executive Officer of SRX Global. “Bringing manufacturing and patient enrollment together at a single, highly regarded academic institution, streamlines logistics while strengthening the overall clinical trial footprint. This progress reinforces our conviction in CERo’s differentiated approach to engineered T cell therapeutics, and we look forward to continuing to support the team as we work toward closing the proposed acquisition.”
Brian Jonas, M.D., Professor, clinician-scientist, and Chief of the Division of Malignant Hematology, Cellular Therapy and Transplantation in the Department of Internal Medicine at the UC Davis School of Medicine and UC Davis Comprehensive Cancer Center and study investigator on the trial, commented, “We are excited to join with CERo Therapeutics to open this important clinical trial site. We look forward to being able to offer a novel and innovative chimeric engulfment receptor-based treatment option for our patients with myeloid malignancies.”
Chris Ehrlich, CERo Therapeutics CEO added, "The addition of UC Davis represents another important milestone in our collaboration, expanding our longstanding relationship beyond manufacturing to include patient enrollment in the CERTAIN-T study. Integrating manufacturing and clinical operations at a single institution has the potential to expand patient access while shortening the time between cell manufacturing and patient infusion. We have been encouraged by the interest we've received from investigators and institutions evaluating participation in the CERTAIN-T trial, and we are pleased to welcome the UC Davis team."
CERo previously reported findings from six patients treated in the first two cohorts of CERTAIN-T. All three patients in the second cohort completed the 28-day dose-limiting toxicity (“DLT”) assessment without a DLT. In its June 2026 update, CERo reported that the observed safety profile remained consistent with earlier findings of no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, DLTs or treatment-related severe adverse events during the DLT assessment window. Investigators reported clinical improvement in two patients, although formal response assessments remained ongoing. One patient with refractory acute myeloid leukemia (“AML”) subsequently underwent allogeneic stem cell transplantation 71 days after CER-1236 infusion. The study has expanded to include myelodysplastic syndromes (“MDS”) and myelofibrosis (“MF”). These clinical results are preliminary and are not sufficient to establish the safety or efficacy of CER-1236.
On October 7, 2026, SRX announced that it had entered into a definitive purchase agreement under which CERo Therapeutics will become a wholly owned subsidiary of SRX Global. The proposed transaction followed SRX’s purchase of senior secured debt in CERo Holdings, announced on August 31, 2026, and remains subject to customary closing conditions.
About the CERTAIN-T Trial
The first-in-human, multicenter, open-label Phase 1/1b CERTAIN-T study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of CER-1236 in patients with hematologic malignancies. The study initially enrolled patients with acute myeloid leukemia (“AML”), including relapsed/refractory AML, AML with measurable residual disease (MRD), and newly diagnosed TP53-mutated AML, and has since expanded to include transfusion-dependent myelodysplastic syndromes (“TD-MDS”), high-risk myelodysplastic syndromes (“HR-MDS”), and post-JAK inhibitor myelofibrosis (“MF”). Primary endpoints include safety and tolerability. Secondary endpoints include pharmacokinetics and measures of clinical response, including overall response rate (“ORR”), complete response (“CR”), composite complete response (“cCR”), and measurable residual disease (“MRD”).
About SRX Global Inc.
SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors.
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering is designed to integrate characteristics of innate and adaptive immunity into a single therapeutic construct intended to engage multiple immune mechanisms against cancer. CERo refers to these engineered cells as Chimeric Engulfment Receptor T cells (“CER-T”).
The Company’s lead investigational product candidate, CER-1236, is being evaluated in hematologic malignancies.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of applicable securities laws. These statements include, without limitation, statements regarding the proposed acquisition of CERo Therapeutics by SRX Global, including its expected timing and completion and the satisfaction of closing conditions; the anticipated benefits of the activation of UC Davis as a clinical trial site, including with respect to patient recruitment and treatment logistics; the clinical development, safety profile, pharmacokinetic and pharmacodynamic characteristics, therapeutic potential, and future evaluation of CER-1236; the progression, design, and enrollment of the CERTAIN-T trial; planned cohort expansion and dose escalation; and SRX Global’s and CERo’s development strategy and objectives. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
Risks and uncertainties include, among others, the possibility that the proposed transaction is not completed on the anticipated timeline or at all; the failure to satisfy closing conditions; the possibility that the activation of additional clinical trial sites does not result in increased patient enrollment; and the risks inherent in the clinical development of CER-1236, an investigational product candidate. Information in this communication regarding CERo, CER-1236 and the CERTAIN-T trial is based on information provided by CERo. Prior to the closing of the proposed transaction, SRX does not control CERo and cannot guarantee CERo’s clinical, regulatory, or business outcomes.
Certain risks that could cause actual results to differ are set forth in SRX Global’s and CERo’s respective filings with the Securities and Exchange Commission, including their most recent Annual Reports on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in these filings are not exhaustive. Forward-looking statements are not guarantees of performance, and undue reliance should not be placed on such statements. SRX Global undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Company Contact
SRX Global Inc.
Kent Cunningham, Chief Executive Officer
Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254
srx@kcsa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does UC Davis’ activation mean for SRXH’s proposed acquisition target CERo?
UC Davis is now a clinical site for CERo’s ongoing CERTAIN-T trial and already serves as CER-1236’s primary manufacturing site. SRX expects combining these roles to expand patient recruitment capacity and streamline treatment logistics.
What clinical results has SRXH disclosed for CERo’s CERTAIN-T trial?
Previously reported findings covered six patients in the first two cohorts, with all three second-cohort patients completing the 28-day assessment without dose-limiting toxicity. Investigators reported clinical improvement in two patients, but formal response assessments remained ongoing. These preliminary findings are not sufficient to establish CER-1236’s safety or efficacy.
What are the endpoints of CERo’s CERTAIN-T trial discussed by SRXH?
The trial’s primary endpoints are safety and tolerability. Secondary endpoints include how the treatment behaves in the body and measures of clinical response, including overall response rate, complete response, composite complete response, and measurable residual disease, a measure of cancer remaining after treatment.